HIV prevention – Medxy AI

Dapivirine Vaginal Ring and Oral PrEP Confirmed Safe for Use During Second Trimester: Insights from the DELIVER Trial

By MedXY 02/14/2026

The Phase 3b DELIVER trial confirms that both the dapivirine vaginal ring and oral PrEP are safe and well-tolerated when initiated in the second trimester of pregnancy, showing no product-related serious adverse events and high rates of term births.

HIV/AIDS news

Infant Safety After In-Utero Exposure to Dapivirine Ring or Oral PrEP: 12‑Month Findings from MTN‑042/DELIVER

By MedXY 11/12/2025

In a randomized phase 3b trial of pregnant women using the dapivirine vaginal ring or daily oral TDF/FTC for HIV prevention, 12‑month infant follow‑up showed no product‑related serious or grade 3+ adverse events and no HIV transmissions, supporting PrEP use in pregnancy.

HIV/AIDS news Specialties Superintelligence

Assessing an AI Chatbot for HIV Prevention in Malaysia: Insights and Usability

By MedXY 08/11/2025

An observational study evaluates an AI chatbot's usability in promoting HIV testing among men who have sex with men in Malaysia, showcasing potential improvements for public health interventions.

HIV/AIDS Medical News news Public Health Specialties

FDA Approves Lenacapavir: A Twice-Yearly Injectable PrEP Transforming HIV Prevention

By MedXY 07/31/2025

Lenacapavir (Yeztugo) becomes the first FDA-approved, twice-yearly injectable PrEP, offering robust long-acting HIV prevention and addressing key adherence barriers.